TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01898013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03469349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin placebo-matching intravenous infusion and tablets.
Study: NCT01393080
Drug: TP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
Study: NCT03616964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00908349
Drug: Oxcarbazepine XR
Normalized name: oxcarbazepine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open Label Study
Study: NCT01699464
Drug: AR-12286 Ophthalmic Solution 0.7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT01699464
Drug: AR-12286 Ophthalmic Solution 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT01951404
Drug: Placebo (for allopurinol)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00241904
Drug: Antiplatelet Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 81 mg q day
Study: NCT02684123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01382498
Drug: Calcium dobesilate (Doxium)
Normalized name: calcium dobesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg, Tablet, Daily, 3 months
Study: NCT00241904
Drug: Beta Blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication
Study: NCT02755701
Drug: Branched-chain Amino Acid
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (livact) will be administered 3 times a day during 24 weeks
Study: NCT02755701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in the same way
Study: NCT00241904
Drug: ACE Inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medications, received 1-2 times per day
Study: NCT01606319
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg every 6 hours as needed
Study: NCT01606319
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 9.4 mg/kg every 6 hours as needed
Study: NCT02484664
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
Study: NCT01601613
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
Study: NCT01657799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to veliparib capsules for oral administration
Study: NCT03437941
Drug: CORT125281
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125281 is supplied as capsules for oral dosing
Study: NCT03437941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match the appearance of the CORT125281
Study: NCT02274077
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01705106
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01705106
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01646684
Drug: SOM230
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02028286
Drug: CLS001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01844726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of placebo (saline)
Study: NCT03771157
Drug: Shingrix vaccine
Normalized name: SHINGRIX vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
Study: NCT02089581
Drug: MRXXX
Normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'MRXXX'. Drug abbreviations can vary and may not be standardized, so without more context about the specific drug or clinical trial, I cannot provide the full generic name. If you have additional details about the drug or trial, please provide that information, and I'll do my best to look up the full generic name.
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRXXX
Study: NCT02089581
Drug: MR1XXX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03119610
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
Study: NCT04004572
Drug: LEAP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given LEAP regimen every 3 weeks for 8 cycles.
Study: NCT01784614
Drug: LY2624803 - Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as reconstituted solution
Study: NCT03502577
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03502577
Drug: Gamma-Secretase Inhibitor LY3039478
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01851707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
Study: NCT01784614
Drug: LY2624803 - Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a capsule
Study: NCT01784614
Drug: Placebo - Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as solution
Study: NCT01784614
Drug: Placebo - Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a capsule
Study: NCT01484561
Drug: CP-690,550 or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
Study: NCT01484561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID orally, approximately 72 days
Study: NCT00520845
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
Study: NCT00220454
Drug: Hydrocortone
Normalized name: Hydrocortone
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00387959
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01015677
Drug: MK-6913
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01015677
Drug: 17-β estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01015677
Drug: Placebo to MK-6913
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01015677
Drug: Placebo to 17-β estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01015677
Drug: MK-6913 25 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04114240
Drug: Xybilun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erectil dysfunction, Viagra generic (sildénafil)
Study: NCT02551744
Drug: proton pump inhibitor group
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole tab 40 mg qd for 6 months.
Study: NCT00872001
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
Study: NCT00258440
Drug: Weekly procrit dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
Study: NCT02761460
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
Study: NCT00562978
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00994786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
Study: NCT01058434
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00366301
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 pills per day
Study: NCT02238197
Drug: Atrovent® Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03184090
Drug: Endocrine therapy (non IMP)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
Study: NCT01660256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00637468
Drug: Intravenous injection of heparin
Normalized name: heparin Injection
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00637468
Drug: Topical use of beta-blocker
Normalized name: Beta-HC Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00637468
Drug: Isovolaemic haemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00637468
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04091360
Drug: Part A: RPL554
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose RPL554 via metered dose inhaler.
Study: NCT04091360
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Study: NCT04091360
Drug: Part B: RPL554
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Study: NCT01150461
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo b.i.d.
Study: NCT02706951
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule; Oral
Study: NCT00511186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
Study: NCT04477993
Drug: Janus Kinase Inhibitor (ruxolitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils \< 500/mm3 or platelets \<50,000/mm3.
Study: NCT01336205
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by the investigator
Study: NCT02632812
Drug: Placebo effervescent granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo effervescent granules (oral), twice daily for 7 days
Study: NCT02632812
Drug: Naproxen tablet
Normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablet 550mg (tablet), twice daily for 7 days
Study: NCT02757313
Drug: Placebo marijuana
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00909532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet given orally q12h for up to 48 weeks
Study: NCT03874936
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: administrated i.v.
Study: NCT03327831
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application followed by activation by ambient sunlight
Study: NCT00571896
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
Study: NCT01743976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo or sugar pill will be taken once daily for 6 weeks
Study: NCT03518242
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03518242
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03518242
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01463228
Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Study: NCT01463228
Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study: NCT01920503
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
Study: NCT00098254
Drug: BAY 43-9006 (Sorafenib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
Study: NCT02406989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MS-553
Study: NCT00818064
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single s.c. injection (per dose cohort)
Study: NCT04253119
Drug: Antiretroviral/Anti HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
Study: NCT02165826
Drug: Standard of Care COPD Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
Study: NCT03421639
Drug: GnRH analog (11.25mg Leuprolide acetate)
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 Leuprolide acetate only one administration
Study: NCT03421639
Drug: Aromatase inhibitor and GnRH analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/day of Anastrazole for 3 months
Study: NCT01002664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 soft-gel placebo capsules Qd for 12 weeks
Study: NCT03833895
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05ug/kg/min Norepinephrine during Cesarean Section Operation
Study: NCT02735837
Drug: placebo topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo topical gel was put into the periodontal pocket using an insulin syringe
Study: NCT00445575
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
Study: NCT00741715
Drug: AVE5530
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily in the evening with dinner
Study: NCT00741715
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily in the evening with dinner
Study: NCT01071837
Drug: APG101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg weekly as intravenous infusion
Study: NCT04585100
Drug: FM101 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-equivalent test (tablet vs oral solution)
Study: NCT04585100
Drug: FM101 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-equivalent test (tablet vs oral solution)
Study: NCT04585100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for 28 days
Study: NCT04585100
Drug: FM101 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM101 (150 mg) BID for 28 days
Study: NCT04585100
Drug: FM101 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM101 (300 mg) BID for 28 days
Study: NCT00569192
Drug: 0.135mg MAP0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
Study: NCT00569192
Drug: 0.25mg MAP0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
Study: NCT00569192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered by nebulization twice daily for 12 weeks
Study: NCT04072445
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04568863
Drug: Melatonin intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
Study: NCT04568863
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
Study: NCT04157036
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery
Study: NCT02270307
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose 50 mg/kg at day +3,+4 once daily
Study: NCT00755456
Drug: PD solution containing glucose
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/2.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
Study: NCT00755456
Drug: PD solution containing glucose and L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
Study: NCT00730821
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00730821
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01507077
Drug: ZGN-440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Study: NCT01507077
Drug: ZGN-440 sterile diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.